Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy

2024-01-23

基因疗法

Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy

Preview

来源: FierceBiotech

GenEdit's NanoGalaxy platform has previously reeled in interest from Lilly and Sarepta.

The next wave of gene editing advances will likely center not only on efficacy but on the diversity of where the therapies can be delivered, and Genentech is signing a new deal to keep up with the competition.

The Roche unit is paying $15 million and offering $629 million in biobucks to use GenEdit’s polymer nanoparticle-based platform to develop gene therapies for autoimmune diseases. GenEdit’s platform, NanoGalaxy, scans through thousands of water-soluble polymers to select tissue-specific candidates that can deliver gene editing payloads. The nanoparticles it builds can range in size, charge and composition, according to the biotech.

The deal with Genentech will center on finding polymers that can support nucleic acid-based medicines for autoimmune diseases. GenEdit’s own internal pipeline, which has so far been kept under wraps, focuses on a range of conditions targeting the nervous system.

It’s unclear how many nanoparticles GenEdit will be supplying Genetech with. The Roche-owned unit will be responsible for all preclinical and clinical development, plus regulatory and commercial work.

The deal is just the latest in pharma and biotech validation for GenEdit. The startup reeled in Eli Lilly as an investor in a $26 million series A back in 2021 and added Sarepta as a partner in February 2022. The muscular dystrophy drug developer gave GenEdit $57 million in near-term payments for up to four targets aimed at neuromuscular indications.

GenEdit is led by CEO Kunwoo Lee, Ph.D., who worked in the lab of Nobel Prize-winning CRISPR scientist Jennifer Doudna, Ph.D. The startup emerged from stealth in 2018 with $8.5 million in funding from Data Collective Bio and SK Holdings, among others.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构